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Abstract Background: Data on the long-term effects of prenatal exposure to maternal cancer
and its treatment on child development are scarce.
Methods: In a multicenter cohort study, the neurologic and cardiac outcomes of 6-year-old
children born to women diagnosed with cancer during pregnancy were compared with the
outcome of children born after an uncomplicated pregnancy. Assessment included clinical
evaluation, comprehensive neuropsychological testing, electrocardiography and echocardiog-
raphy.
Results: In total, 132 study children and 132 controls were included. In the study group, 97
children (73.5%) were prenatally exposed to chemotherapy (alone or in combination with
other treatments), 14 (10.6%) to radiotherapy (alone or in combination), 1 (0.8%) to trastuzu-
mab, 12 (9.1%) to surgery alone and 16 (12.1%) to no treatment. Although within normal
ranges, statistically significant differences were found in mean verbal IQ and visuospatial
long-term memory, with lower scores in the study versus control group (98.1, 95% confidence
interval [CI]: 94.5e101.8, versus 104.4, 95% CI: 100.4e108.4, P Z 0.001, Q < 0.001 [Q refers
to the false discovery rate adjusted P value], and 3.9, 95% CI: 3.6e4.3, versus 4.5, 95% CI: 4.1
e4.9, P Z 0.005, Q Z 0.045, respectively). A significant difference in diastolic blood pressure
was found, with higher values in chemotherapy-exposed (61.1, 95% CI: 59.0 to 63.2) versus
control children (56.0, 95% CI 54.1 to 57.8) (P < 0.001, Q < 0.001) and in a subgroup of
59 anthracycline-exposed (61.8, 95% CI: 59.3 to 64.4) versus control children (55.9, 95% CI:
53.6 to 58.1) (P < 0.001, Q Z 0.02).
Conclusions: Children prenatally exposed to maternal cancer and its treatment are at risk for
lower verbal IQ and visuospatial long-term memory scores and for higher diastolic blood pres-
sure, but other cognitive functions and cardiac outcomes were normal at the age of 6 years.
Clinical trial registration: The study is registered at ClinicalTrials.gov, NCT00330447.
ª 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Cancer during pregnancy is a challenge, as the health of
both the mother and foetus has to be considered in
therapeutic decision-making. Over the past 20 years,
clinical management of pregnant cancer patients has
evolved with a higher number of patients receiving
treatment during pregnancy, less terminations of preg-
nancy and less medically induced preterm deliveries [1].
Cancer treatment may have acute and/or chronic side-
effects on the foetus, including neurotoxicity and car-
diotoxicity, as chemotherapy may cross the placenta in
varying amounts [2,3]. In addition, cancer may be
accompanied by maternal stress, inflammatory re-
actions, exposure to radiation, anaesthetic agents and
other medications, potentially influencing foetal devel-
opment. Notwithstanding, data on the short- and long-
term impact on foetal development are still limited [4].
Our group previously published two studies, doc-
umenting reassuring health status, cognitive and cardiac
outcomes at a median age of 22 months [5,6]. However,
cognitive problems may become more apparent at
school age and can be more accurately evaluated at
older ages. Moreover, cardiac problems may develop
many years after chemotherapy exposure [7,8]. There-
fore, this study aims to investigate the health status and
cognitive and cardiac outcome of 6-year-old children
prenatally exposed to maternal cancer and its
treatment and, in particular, to chemotherapy.
2. Material and methods
2.1. Study participants
This is a multicenter cohort study including children
born to women diagnosed with cancer during pregnancy
(with or without treatment during pregnancy) (study
group). At predefined ages (1.5, 3, 6, 9, 12, 15 and 18
years), the children are invited for follow-up. In this
study, we compare the outcome of 6-year-old children
from the study group with children born after an un-
complicated pregnancy (control group). Study children
were identified and enrolled prospectively (during
pregnancy or between birth and 6 years) and evaluated
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at six referral centres in Belgium, the Netherlands, the
Czech Republic and Italy, all members of the
International Network on Cancer, Infertility and Preg-
nancy. Control children were identified and enrolled at
the age of 6 years. For the neurocognitive tests and
health examination, the study and control children were
1:1 matched for country, gender, age, gestational age at
birth and language of the tests. For the cardiac
examinations, children were 1:1 matched for gender and
age. The study design and recruitment are summarised
in Fig. 1. Details on the recruitment and exclusion
criteria are provided in the Methods section in the data
article. Ethical approval was obtained by each institu-
tion, and the parents of each child provided written
informed consent to participate. The full study protocol
is available at http://www.cancerinpregnancy.org/study-
protocols.
2.2. Study testing and outcomes
Oncological, obstetrical and neonatal data were
collected. Cognitive development was examined using a
comprehensive neuropsychological test battery to assess
intelligence, memory, attention and behaviour problems
(Table 1).
Cardiac evaluation included a 12-lead electrocardio-
gram and an echocardiographic examination performed
according to American Society of Echocardiography
guidelines. The primary cardiac outcome was left
ventricular shortening fraction measured by M-mode.
Secondary outcomes included the cardiac chamber di-
mensions (left and right ventricular end diastolic
diameter, left ventricular posterior wall thickness,
interventricular septum thickness), left ventricular ejec-
tion fraction, the mitral valve E and A velocity and E/A
ratio, tissue Doppler imaging velocities at the left and
right ventricular wall and interventricular septum and
the longitudinal and circumferential 2D-strain
measurements by speckle-tracking echocardiography.
Study children underwent a clinical neurological and
general paediatric examination, and the parents filled
out a health questionnaire. The incidence rates of health
problems were considered as secondary outcomes.
Details on the neuropsychological and echocardio-
graphic protocol and the health questionnaire are
provided in the Methods section in the data article.
2.3. Statistical analysis
We converted raw scores into standardised scores for
the intelligence tests and behaviour questionnaires,
Pregnant women with cancer were registered by the
International Network on Cancer, Infertility and 
Pregnancy 
Children from the general population born to healthy 
mothers, after uncomplicated pregnancy and delivery 
were recruited as controls
Informed consent was obtained for 161 children born to 
mothers with cancer during pregnancy
136 children were assessed at the age of 6 years
25 excluded
11 due to study discontinuation in participating center Nijmegen
6 no further interest in follow-up examinations
3 distance to the hospital too far + don’t want to burden the child
1 due to disease condition of mother
1 moved abroad
1 only speaks foreign languages
1 because of the presence of a syndromal entity, making study
examinations impossible
1 lost to follow-up
132 children were included in the analysis 
4 excluded due to lack of controls
132 control children were included in the analysis
Fig. 1. Study design and recruitment. This cohort of 132 children evaluated at the age of 6 years includes 83 children who underwent
cognitive evaluation and 28 children who underwent cardiac examinations in our previously published 1.5e3 years cohort study [6]. The
results of 12 children at the age of 6 years were previously published [5], whereas 120 children underwent new testing. Longitudinal
analyses will be performed when we reach our sample size in the oldest age group.
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based on normative data for each country provided by
the test. For the memory tests, raw subtest-scores were
used. Reaction times and percentage of errors were
obtained for the attention tasks. Univariate analyses of
covariance (ANCOVA) were used to investigate
between-group differences in cognitive outcome and
behaviour with education levels of parents as cova-
riates. A subgroup analysis was performed in
chemotherapy-exposed children versus controls. In
addition, the incidence of behaviour problems was
compared with matched controls for children whose
mothers died and for those with surviving mothers.
Post hoc, verbal IQ was compared between children
exposed to different types of chemotherapy and their
matched controls and between children whose mothers
died versus those with surviving mothers and their
matched controls. The associations between cognitive
outcome and gestational age or the number of
chemotherapy cycles were investigated using Pearson
correlations. The Spearman’s rank-correlation coeffi-
cient was used to investigate the relationship between
cognitive outcome and the estimated foetal dose of
radiation.
Echocardiographic measures were obtained in three
cardiac cycles and averaged. Between-group differences
were investigated using univariate analysis of variance
(ANOVA). A subgroup analysis was performed in
anthracycline-exposed children versus controls.
Q values, which represent false discovery rate
adjusted P values, were calculated to correct for multiple
testing [9]. A two-sided Q value of less than 0.05 was
considered to indicate statistical significance.
3. Results
3.1. Characteristics of the children
In total, 132 children (including five pairs of dizygotic
twins) born to mothers diagnosed with cancer during
pregnancy were included, of whom 88 from Belgium, 25
from the Netherlands, 12 from Italy and 7 from the
Czech Republic. During pregnancy, 97 children (73.5%)
were exposed to chemotherapy (alone or in combination
with other treatments), 14 (10.6%) to radiotherapy
(alone or in combination), 1 (0.8%) to trastuzumab, 12
(9.1%) to surgery alone and 16 children (12.1%) were
born to mothers not treated during pregnancy (Table 2).
Twenty-five mothers (19.7%) died before the child was 6
years old. Additional information about the maternal
cancer types and specific treatments is provided in
Tables 1, 2 and eTable 1e6, all in the data article.
Table 2
Cancer treatment during pregnancy for all children and those categorised as small for gestational age in singleton pregnancies.
Cancer treatment All children (N Z 132)
Number (%)
Small for gestational age (N Z 18)
Number (% of children with treatment, excluding twins)
Surgery 12 (9.1)a 1 (10.0)
Chemotherapy 38 (28.8) 9 (23.7)
Radiotherapy 1 (0.8) 0 (0.0)
Surgery and chemotherapy 51 (38.6)a 5 (11.1)
Surgery and radiotherapy 5 (3.8) 2 (40.0)
Surgery, chemotherapy and radiotherapy 8 (6.1)a 0 (0.0)
Trastuzumab 1 (0.8) 0 (0.0)
No treatment 16 (12.1) 1 (6.3)




Outcome measure Test used
Primary outcome
Full scale intelligence Wechsler Preschool and Primary Scale of
Intelligenceethird edition (WPPSI-III) [26]
Secondary outcomes
Verbal intelligence, performance intelligence and processing speed Wechsler Preschool and Primary Scale of
Intelligenceethird edition (WPPSI-III) [26]
Verbal and visuospatial memory span, visuospatial short- and
long-term memory, verbal working memory and short- and
long-term memory for faces
Children’s Memory Scale (CMS) [27]
Alertness, divided attention, selective attention and response inhibition Amsterdam Neuropsychological Tasks (ANT) [28]
Internalising and externalising behaviour problems Child Behavior Checklist (CBCL) [29]
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In general, demographic and perinatal characteristics
were comparable between the study and control group
(Table 3 and eTable 7e10 in the data article).
3.2. Perinatal outcome and growth
In the cancer group, median gestational age at birth was
36.1 weeks (range: 27.4e40.7) and median birth weight
was 2705 g (range: 720e4200). Eighty children (60.6%)
were born preterm (versus 6.8e8.0% in the participating
countries) [10], of whom 8 (6.1%) very preterm
(27.0e31.9 weeks gestational age), 16 (12.1%)moderately
preterm (32.0e33.9 weeks) and 56 (42.4%) late preterm
(34.0e36.9 weeks) and 52 children (39.4%) were born at
term (37.0 weeks or later). The number and type of the
registered congenital malformations were not different
from the general population (eTable 11 in the data
article). After exclusion of twins, 18/121 children (14.9%)
in the study group were born small for gestational age
(i.e. a birth weight below the tenth percentile of gender-
and gestational ageematched children) versus 7/119
(5.9%) in the control group (eTable 12 in the data article).
Biometric data at 6 years were comparable between the
groups (eFigs. 1 and 2 in the data article).
3.3. Cognitive development and behaviour
Median age at cognitive evaluation was 6.1 and 6.2 years
in the study and control group, respectively. The
difference in estimated marginal means of the primary
outcome full scale IQ was not statistically significant
between the study group (98.9, 95% confidence interval
[CI]: 95.2 to 102.6) and the control group (103.0, 95%
CI: 98.9 to 107.0) (P Z 0.03, Q Z 0.15) (eTable 13 and
eFig. 3 in the data article) or between the subgroup of
chemotherapy-exposed children (101.4, 95% CI: 93.7 to
109.1) and controls (106.0, 95% CI: 98.0 to 114.0)
(P Z 0.04, Q Z 0.17) (Fig. 2A) (eTable 14 in the data
article). Full scale IQ was not related to gestational age
in the chemotherapy-exposed group (r Z 0.04,
P Z 0.74) and the control group (r Z 0.08, P Z 0.43)
(Fig. 2B), to the number of chemotherapy cycles
(r Z 0.04, P Z 0.74) (Fig. 2C) or to the dose of radia-
tion (r Z 0.19, P Z 0.52) (eFig. 4 in the data article).
With regard to the secondary outcomes, the differ-
ence in estimated marginal means of verbal IQ was
statistically significant, with lower values in the study
group (98.1, 95% CI: 94.5 to 101.8) than the control
group (104.4, 95% CI: 100.4 to 108.4) (P Z 0.001,
Q < 0.001) and in chemotherapy-exposed children
(101.7, 95% CI: 94.3 to 109.0) than their matched con-
trols (108.5, 95% CI: 100.8 to 116.1) (P Z 0.002,
QZ 0.03). Post hoc, we evaluated the possible impact of
death of the mother on verbal IQ. The size of the
between-group difference in verbal IQ was larger in
children whose mother died (15.1 IQ points) than those
with surviving mothers (4.9 points) (eTable 16 in the
data article). There were no statistically significant
Table 3
Demographic characteristics of the children included in cognitive and health examinations.
Characteristic Cancer during pregnancy group (N Z 132) Control group (N Z 132) P value
Median age (range) e years 6.1 (4.8e7.9) 6.2 (4.7e7.7) 0.29
Median gestational age (range) e weeks 36.1 (27.4e40.7) 36.1 (28.6e41.0) 0.65
Median birth weight (range) e grams 2705 (720e4200) 2713 (1025e4400) 0.73
Median maternal age at birth of this child (range) e years 33 (19e44) 31 (20e46) 0.02
Sex e number (%) 1.00
Male 71 (53.8%) 71 (53.8%)
Female 61 (46.2%) 61 (46.2%)
Race e number (%)a 0.27
White 115 (87.1%) 119 (90.2%)
Black 11 (8.3%) 5 (3.8%)
Other 6 (4.5%) 8 (6.1%)
Highest level of education of parents e number (%)b
Mother 0.07
Primary school 5 (3.8%) 2 (1.5%)
Secondary school 52 (39.4%) 34 (25.8%)
Bachelor 42 (31.8%) 53 (40.1%)
Master’s degree or higher 33 (25.0%) 41 (31.1%)
Unknown 0 (0.0%) 2 (1.5%)
Father 0.69
Primary school 7 (5.3%) 5 (3.8%)
Secondary school 58 (43.9%) 51 (38.6%)
Bachelor’s degree 33 (25.0%) 32 (24.2%)
Master’s degree or higher 32 (24.2%) 39 (29.5%)
Unknown 2 (1.5%) 5 (3.8%)
a Race was self-reported by the parents.
b The highest level of education is presented according to the European educational system. A bachelor’s degree is earned at both traditional
universities and non-university institutions of higher education and requires between three and four years of full-time study. A master’s degree is
earned at university and requires one to two years of full-time study after a bachelor’s degree.
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between-group differences in performance IQ or pro-
cessing speed (Fig. 2A) (eTables 13-14 in the data
article). With regard to memory, the difference in esti-
mated marginal means of visuospatial long-term mem-
ory was statistically significant, with lower values in the
study group (3.9, 95% CI 3.6 to 4.3) than the control
group (4.5, 95% CI: 4.1 to 4.9) (P Z 0.005, Q Z 0.045)
and in chemotherapy-exposed children (4.0, 95% CI: 3.3
to 4.8) than their controls (4.7, 95% CI: 3.9 to 5.5)
(P Z 0.005, Q Z 0.045) (eTables 17e18 in the data
article). No statistically significant differences were
found in memory span, short-term memory, attention or
behaviour problems between the study and control
group and between chemotherapy-exposed and control
children (Fig. 2D and E) (eTable 17e22 in the data
article). The differences in internalising and external-
ising behaviour problems were also not statistically
significant for study children whose mothers died and
those with surviving mothers compared with their
matched controls (eTable 23 in the data article).
3.4. Cardiac evaluation
Cardiac evaluation was performed in 78 chemotherapy-
exposed children and matched controls. Median age was
6.1 and 6.2 years in the chemotherapy-exposed and
Fig. 2. Cognitive outcome. (A) Comparison of the mean full scale IQ, verbal IQ, performance IQ and processing speed between the
chemotherapy-exposed group and the control group. The mean of standardised IQ-scores is 100 with a standard deviation of 15 and scores
between 90 and 110 are considered average. Higher scores indicate more advanced development. (B) The relation between full scale IQ and
gestational age at birth (in weeks) for the chemotherapy-exposed and control group. Values of children from the chemotherapy-exposed
group are represented by circles, and those of children from the control group are represented by crosses. Mean values (as calculated by
linear regression) are indicated by a solid line for the chemotherapy-exposed group and a dashed line for the control group. (C) The
relation between full scale IQ and the number of chemotherapy cycles administered during pregnancy. (D) Comparison of the raw
memory scores from the subtests of the Children’s Memory Scale between the chemotherapy-exposed group and the control group. Verbal
memory was measured using the subtest numbers (range of scores between 0 and 14 for numbers forward [verbal memory span] and 0e12
for numbers backward [verbal working memory]). Visuospatial short- and long-term memory was measured using the subtest dot lo-
cations (range: 0e6). Visuospatial memory span was measured using the subtest picture locations (range: 0e30). Higher scores indicate
more advanced memory skills. (E) Comparison of the standardised T-scores for internalising and externalising behaviour problems on the
Child Behavior Checklist between the chemotherapy-exposed group and the control group. The mean of standardised T-scores is 50 with a
standard deviation of 15. Higher scores indicate more behaviour problems. (A), (D), (E): The figures show estimated marginal means with
standard errors of the means for each group and variable. Raw P values and false discovery rate adjusted P values (Q values) are
presented.
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control group, respectively. No statistically significant
between-group differences in body surface area, heart
rate and systolic blood pressure were found. The dif-
ference in means of diastolic blood pressure was statis-
tically significant, with higher values in chemotherapy-
exposed (61.1, 95% CI: 59.0 to 63.2) versus control
children (56.0, 95% CI: 54.1 to 57.8) (P < 0.001,
Q < 0.001) and in a subgroup of 59 anthracycline-
exposed (61.8, 95% CI: 59.3 to 64.4) versus control
children (55.9, 95% CI: 53.6 to 58.1) (P < 0.001,
Q Z 0.02) (Table 4 and eTable 24 in the data article).
Electrocardiographic evaluation did not reveal rhythm
or conduction abnormalities. On echocardiographic
examination, no structural abnormalities were detected
in any of the children. The difference in means of the
primary outcome left ventricular shortening fraction
was not statistically significant between chemotherapy-
exposed and control children. In addition, no statisti-
cally significant between-group differences were found
in secondary outcomes.
3.5. Health problems
The incidence of health problems and the need for sur-
gery or care as reported by the parents were mostly
comparable between the study and control group, but
children from the study group were 3 times more likely
to wear glasses than the controls (14.9 versus 5.0%)
(eTable 25 in the data article). Of 14 children exposed to
cisplatin, hearing loss was determined in 3 of 8 children
with available audiometric data (eTable 26 in the data
article). General paediatric and clinical neurological
examinations were normal in 96 of 103 study children
(93.2%) undergoing examination (eTable 27 in the data
article).
4. Discussion
In this multicenter prospective cohort study, cognitive
development, health problems and growth were
compared between 132 children born to mothers diag-
nosed with cancer during pregnancy and non-exposed
matched controls and between a subgroup of 97
chemotherapy-exposed children and controls. The car-
diac structure and function were also evaluated in 78
chemotherapy-exposed children and controls.
The differences in cognitive outcomes on most tests
were not statistically significant between the study and
control group and between the chemotherapy-exposed
subgroup and controls. Especially, there were no sta-
tistically significant between-group differences in the
primary outcome full scale IQ. In addition, full scale IQ
was not related to the number of chemotherapy cycles
administered during pregnancy or to the estimated
foetal dose of radiation. No statistically significant dif-
ferences were found in performance IQ and processing
Fig. 2. (continued).
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Table 4
Echocardiographic data and other measurements of cardiac function.
Measurement No. Chemotherapy-exposed group (N Z 78) Control group (N Z 78) Type 3 test of fixed effects
Mean S.E. 95% CI Mean S.E. 95% CI F P value Q value Partial eta squared
Lower Upper Lower Upper
Body surface area (m2) 153 0.84 0.01 0.83 0.86 0.84 0.01 0.82 0.86 0.05 0.83 0.95 0.000
Blood pressure (mm Hg)
Systolic 134 102.61 1.23 100.19 105.04 99.71 1.05 97.63 101.80 3.22 0.08 0.30 0.024
Diastolic 134 61.11 1.08 58.97 63.24 55.97 0.93 54.14 57.81 13.02 <0.001 <0.001 0.090
Heart rate (beats/min) 155 82.48 1.35 79.82 85.15 82.36 1.34 79.71 85.01 0.004 0.95 0.99 0.000
Left ventricular shortening fraction (%) 156 36.31 0.50 35.33 37.30 37.14 0.50 36.16 38.13 1.38 0.24 0.60 0.009
Left ventricular ejection fraction (%) 156 66.84 0.63 65.60 68.09 67.93 0.63 66.68 69.17 1.48 0.23 0.60 0.010
End diastolic diameter (cm)
Left ventricular 156 3.59 0.03 3.53 3.65 3.65 0.03 3.59 3.71 2.18 0.14 0.49 0.014
Right ventricular 152 1.57 0.03 1.52 1.62 1.60 0.03 1.55 1.65 0.77 0.38 0.71 0.005
Left ventricular posterior wall thickness (cm) 156 0.53 0.01 0.51 0.55 0.54 0.01 0.52 0.55 0.07 0.80 0.95 0.000
Interventricular septum thickness (cm) 156 0.52 0.01 0.51 0.54 0.54 0.01 0.53 0.56 3.73 0.06 0.26 0.024
Mitral valve E velocity (m/s) 153 1.01 0.02 0.98 1.04 1.07 0.02 1.04 1.10 6.60 0.01 0.13 0.042
Mitral valve A velocity (m/s) 152 0.53 0.01 0.50 0.55 0.57 0.01 0.55 0.60 5.95 0.02 0.13 0.038
Mitral valve E/A ratio 152 1.98 0.05 1.88 2.09 1.95 0.05 1.85 2.05 0.23 0.63 0.84 0.002
Basal segment of left ventricular lateral wall (cm/sec)a
Peak systolic velocity 139b 8.90 0.25 8.41 9.40 9.09 0.23 8.63 9.54 0.30 0.59 0.84 0.002
Peak early diastolic velocity 140b 17.39 0.33 16.74 18.05 17.76 0.31 17.15 18.37 0.65 0.42 0.72 0.005
Peak late diastolic velocity 134b 6.12 0.21 5.71 6.54 6.04 0.20 5.65 6.44 0.08 0.78 0.95 0.001
Basal segment of interventricular septum (cm/sec)a
Peak systolic velocity 143b 7.24 0.15 6.94 7.54 7.71 0.14 7.44 7.99 5.28 0.02 0.14 0.036
Peak early diastolic velocity 143b 13.70 0.22 13.26 14.13 13.55 0.20 13.15 13.95 0.24 0.62 0.84 0.002
Peak late diastolic velocity 141b 5.74 0.14 5.45 6.02 5.73 0.13 5.47 6.00 0.000 0.99 0.99 0.000
Basal segment of right ventricular lateral wall (cm/sec)a
Peak systolic velocity 138b 12.81 0.25 12.33 13.30 13.04 0.23 12.58 13.49 0.44 0.51 0.81 0.003
Peak early diastolic velocity 139b 15.66 0.32 15.03 16.29 15.69 0.30 15.10 16.28 0.004 0.95 0.99 0.000
Peak late diastolic velocity 137b 9.08 0.27 8.55 9.62 9.46 0.25 8.96 9.96 1.02 0.31 0.68 0.008
Global left ventricular longitudinal strain (%) 127b 20.61 0.31 20.00 21.21 21.00 0.29 20.42 21.57 0.85 0.36 0.71 0.007
Global left ventricular circumferential strain (%) 109b 21.20 0.48 20.25 22.15 20.49 0.38 19.74 21.24 1.34 0.25 0.60 0.012
a Measurements were obtained with the use of tissue Doppler imaging.


















































speed. However, children from the study group and
children exposed to chemotherapy scored on average 6
points lower on verbal IQ than their matched controls.
Although the difference was statistically significant, the
clinical relevance may be limited as the values were
within the normal range and the between-group differ-
ence was smaller than one standard deviation (i.e. 15 IQ
points). A study in preterm infants showed that
increased amount of adult talk during the neonatal
intensive care unit stay may contribute to higher
cognitive and language outcomes at 7 and 18 months
corrected age [11]. In the case of cancer during preg-
nancy, motherechild interactions in the neonatal period
and early years of life may be more restricted because of
the maternal disease and treatment or even absent in the
case of maternal death. Our data support this hypoth-
esis, as verbal IQ was more affected in children whose
mothers died than in children with surviving mothers.
Furthermore, the visuospatial long-term memory score
was significantly lower in the study group and in the
chemotherapy-exposed subgroup than those in their
matched controls, although attention, memory span and
short-term memory were not affected. This is in contrast
with studies on childhood cancer survivors mostly
reporting working memory and attention deficits and
slower information processing speed [12].
Notwithstanding the encountered differences in ver-
bal IQ and visuospatial long-term memory and given the
large range of cognitive functions assessed in this study,
most cognitive functions were normal at the age of 6
years. This is largely consistent with our previous find-
ings in the 1.5e3 years cohort and other studies,
reporting minor to no statistically significant differences
or results within normal ranges [5,6,13e15].
In our study, 60.6% of children were born preterm,
which may result from elective induction of delivery as
part of treatment strategies to limit ongoing exposure of
the foetus to cancer treatment or from spontaneous
preterm labour which may have various cancer-related
and cancerenon-related causes. In the 1.5e3 years
cohort, prematurity was associated with a worse cogni-
tive outcome [6]. This relationship was no longer present
at the age of 6 years with regard to full scale IQ.
Inconsistent findings have been reported on the long-
term effects of preterm birth on cognition, especially
for late preterm born children, who are the most rep-
resented preterm born children in our study [16e19].
The cardiac evaluation in chemotherapy-exposed
children was overall reassuring. No statistically signifi-
cant between-group differences in cardiac dimension
and global function measurements including tissue
Doppler imaging and strain analyses were found, and all
measurements were within normal ranges. However, the
diastolic blood pressure was higher in chemotherapy-
exposed and anthracycline-exposed versus control chil-
dren, but the clinical relevance may be limited. The
overall normal cardiac findings are consistent with our
previous findings in the 3-year-old cohort and other
studies [6,20e22].
The incidence of health problems was comparable
between study and control children, but children from
the study group were three times more likely to wear
glasses than the controls. An association with cancer
treatment is possible as the development of the eyes and
central nervous system takes place throughout the entire
pregnancy and needs further investigation. In addition,
three children exposed to cisplatin were diagnosed with
hearing loss. Cisplatin has also been related to ototox-
icity in adults and children with cancer [23]. Ototoxicity
is associated with declines on intellectual and academic
performances and worse social and langauge develop-
ment [24,25]. Where possible, cisplatin should be
replaced by carboplatin with a more favourable toxicity
profile. Long-term surveillance of auditory function of
children prenatally exposed to platinum-based treat-
ment is recommended.
Our study has some limitations. As cancer may have
been present before the start of pregnancy and/or in
some cases termination of pregnancy is indicated or
preferred by the couple, a selection bias may be present
towards a healthier subset of the eligible population and
malignancies not necessitating chemotherapy during the
first trimester. The results cannot be extrapolated to all
types of chemotherapeutic agents and to all trimesters of
pregnancy. Individual drug evaluation was not possible
because of the frequent combination of different cancer
treatments.
5. Conclusions
Children prenatally exposed to maternal cancer, the
associated stress, diagnostic imaging and treatments
have cognitive and cardiac outcomes within normal
ranges at the age of 6 years. However, they are at risk
for lower verbal IQ and visuospatial long-term memory
scores and for higher diastolic blood pressure than
matched controls. In addition, they are at higher risk for
need for glasses and ototoxicity in case of cisplatin
exposure. In accordance with earlier studies, our data
show that in many cases, the risks of maternal cancer
treatment during pregnancy do not outweigh the benefit
of maternal treatment delay or the need for termination
of pregnancy. The results of our study will help patients
to make well-informed decisions.
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